Holen Sie sich die Stockscreener-App
288.94
0.18%
0.53
Handel nachbörslich:
288.00
-0.94
-0.33%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$288.41
Offen:
$285.89
24-Stunden-Volumen:
1.30M
Relative Volume:
0.74
Marktkapitalisierung:
$56.45B
Einnahmen:
$310.23B
Nettoeinkommen (Verlust:
$1.69B
KGV:
33.52
EPS:
8.62
Netto-Cashflow:
$3.58B
1W Leistung:
-0.79%
1M Leistung:
-0.64%
6M Leistung:
+18.71%
1J Leistung:
+22.09%
1-Tages-Spanne:
$285.24
$289.75
1-Wochen-Bereich:
$285.24
$296.70
52-Wochen-Spanne:
$218.65
$309.35
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Vergleichen Sie COR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
288.94 | 56.45B | 310.23B | 1.69B | 3.58B | 8.62 |
|
MCK
Mckesson Corporation
|
712.89 | 89.94B | 359.05B | 3.30B | 5.23B | 25.83 |
|
CAH
Cardinal Health Inc
|
154.71 | 36.86B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
70.37 | 8.75B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.37 | 578.29M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
Cencora Enhances Financial Flexibility with Credit Amendments - TipRanks
Cencora IncIncreases Revolving Credit Facility To $4.5 Billion - marketscreener.com
Here's Why You Should Add Cencora Stock to Your Portfolio Now - MSN
Cravath Advises on €1B Cencora Notes Offering - Lawyer Monthly
Mizuho Adjusts Price Target on Cencora to $316 From $315, Maintains Outperform Rating - marketscreener.com
Wells Fargo Upgrades Cencora (COR) Stock to Overweight, Lifts PT - MSN
Cardinal Health stock, Cencora stock upgraded at Wells Fargo - Seeking Alpha
Wells Fargo Upgrades Cencora (COR) - Nasdaq
Wells Fargo upgrades Cencora stock rating, raises price target to $337 - Investing.com
Wells Fargo Upgrades Cencora (COR) with Raised Price Target | COR Stock News - GuruFocus
Assessing Cencora: Insights From 6 Financial Analysts - Benzinga
Cencora (COR) Receives Upgrade as Analysts Set New Price Target - GuruFocus
Cencora (COR) Receives Upgrade as Analysts Set New Price Target | COR Stock News - GuruFocus
Wells Fargo Elevates Cencora (COR) to Overweight with Raised Price Target | COR Stock News - GuruFocus
Insider Sell Alert: Lazarus Krikorian Sells 3,000 Shares of Cencora Inc (COR) - GuruFocus
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cencora, Inc. Declares Quarterly Cash Dividend, Payable on June 2, 2025 - marketscreener.com
Nephron Research Adjusts Cencora Price Target to $335 From $325 - marketscreener.com
Cencora, Inc. (COR) Announces Board Changes: New Appointment and Resignation - GuruFocus
Cencora appoints new board member to boost growth By Investing.com - Investing.com South Africa
Cencora Announces New Board Appointment Amid Recent Resignation - TipRanks
Cencora Appoints Lori J. Ryerkerk To Board - citybiz
Cencora Elects Lori J. Ryerkerk to Its Board of Directors | COR Stock News - GuruFocus
Cencora appoints new board member to boost growth - Investing.com
Cencora Elects Lori J. Ryerkerk To Its Board Of Directors - marketscreener.com
Global Supply Chain Expert and Former Fortune 500 CEO Lori Ryerkerk Strengthens Cencora Board - Stock Titan
Baird Adjusts Price Target on Cencora to $351 From $350, Maintains Outperform Rating - marketscreener.com
Beat the Market the Zacks Way: GE Aerospace, Monster Beverage, Cencora in Focus - MSN
Cencora Completes €1 Billion Senior Notes Sale - TipRanks
Insider Sell: Steven Collis Sells Shares of Cencora Inc (COR) - GuruFocus
Cencora, Inc. (COR) Announces €1 Billion Senior Notes Offering - GuruFocus
Cencora Enters €1 Billion Senior Notes Agreement - TipRanks
Robust Results Lifted Cencora (COR) Amid Upgraded Outlook - Insider Monkey
Jim Cramer Highlights Cencora (COR) “Knocked It Out of The Park” - Insider Monkey
8 Stocks on Jim Cramer’s Radar Recently - Insider Monkey
Cencora, Inc. concludes securities offering without stabilisation action By Investing.com - Investing.com Nigeria
Insider Sell Alert: Lon Greenberg Sells 3,000 Shares of Cencora Inc (COR) - GuruFocus
Cencora Director Sells Stock in Major Transaction - TipRanks
Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs - Seeking Alpha
Cencora, Inc. concludes securities offering without stabilisation action - Investing.com
Cencora, Inc. announces potential market stabilization measures By Investing.com - Investing.com South Africa
Cencora Reports Strong Q2 2025 Results, Raises Outlook - MSN
Cencora Files For Two-Part Senior Notes Offering Size Not Disclosed- SEC Filing - marketscreener.com
Cencora, Inc. announces potential market stabilization measures - Investing.com
Cencora increases FY2025 EPS guidance to $15.70-$15.95 amid specialty growth - MSN
Cencora's (NYSE:COR) Soft Earnings Don't Show The Whole Picture - Yahoo Finance
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):